Skip to content

Effect of Dangguijakyaksan on climacteric syndrome: a randomized, double-blind, placebo-controlled pilot trial

Effect of Dangguijakyaksan on climacteric syndrome: a randomized, double-blind, placebo-controlled pilot trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0002387
Enrollment
34
Registered
2017-07-25
Start date
2017-07-07
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sponsors

Korea Institute of Oriental Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) 45-60 years (2) Menopausal and female climacteric statesd(menopause includes both natural menopause and induced menopause) (3) Menopause rating scale (MRS) score of 9 or more (4) Those who blood-deficiency survey score more than 30 points (5) A person who has received sufficient explanation of the clinical trial and agrees to participate and signs the consent form

Exclusion criteria

Exclusion criteria: (1) A person who received hormone replacement therapy within 3 months of screening visit (2) A person who received oriental-medicine treatment for the purpose of improving symptoms of menopausal symptoms within 4 weeks of screening visit (3) A person who took health functional food or medicines for the purpose of improving symptoms of menopausal symptoms within 4 weeks of screening visit (4) A person who has severe mental illnesses such as depression and anxiety disorder, or who is currently taking psychotropic drugs such as antidepressants (5) A person who has uncontrolled thyroid disease (those who are considered to be able to participate in this trial by the tester can participate) (6) A person whose AST, ALT, ALP, and GGT exceed 1.5 times the normal upper limit (7) A person whose BUN(Blood urea nitrogen), creatinine 1.5 times the normal upper limit (8) A person who is currently receiving transfusion or erythropoietin treatment for severe anemia (9) A menopausal women with unexplained vaginal bleeding (10) A person with with lactose intolerance (11) A person who is currently participating in other clinical trials (12) If the other clinical trial officer judges that it is inappropriate

Design outcomes

Primary

MeasureTime frame
Menopause Rating Scale(MRS)

Secondary

MeasureTime frame
Korean Version of World Health Organization Quality of Life-BREF, WHOQOL-BREF;Blood-deficiency survey;Follicle Stimulating Hormone(FSH);Estradiol(E2);lean body mass

Countries

Korea, Republic of

Contacts

Public ContactEunji Park

Dunsan Korean Medicine Hospital of Daejeon University

pej3153@naver.com+82-42-470-9661

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 7, 2026